Updated:
Negev Capital
Negev Capital is a psychedelic medical intervention investment fund with assets of USD$30+ million. The Company invests in drug discovery, with a focus on...
Negev Capital
Negev Capital is a psychedelic medical intervention investment fund with assets of USD$30+ million. The Company invests in drug discovery, with a focus on preclinical and/or Phase 1 stages of development. They aim to support those early-stage companies in need of capital that promote the thoughtful, responsible, medical use of psychedelic medication for psychiatric disorders, and who have excellent management and science teams, and solid IP.
General information
Firm type
Venture Capital
Year founded
2021
AUM
Undisclosed
Location
Region
Americas
Country
Cayman Islands
City
Grand Cayman
Corporate office
Grand Cayman, Cayman Islands
Sector focus
Frequently asked questions
What therapeutic areas does Negev Capital target?
Negev Capital is exclusively dedicated to central nervous system and brain health therapeutics. The firm invests in biotech companies developing treatments for neurological and psychiatric conditions. This singular focus sets it apart from generalist life sciences investors who spread capital across oncology, rare disease, and other broader categories.
Is the fund currently making new investments?
The firm describes its fund as fully invested, which means it has completed its deployment period and is not actively making new commitments from the current vehicle. Primary activity at this stage centers on supporting existing portfolio companies and executing exits. Any new investments would depend on a subsequent fundraise, which has not been publicly announced.
Which large pharmaceutical companies have acquired Negev Capital portfolio companies?
Publicly disclosed exits from the Negev Capital portfolio include acquisitions by AbbVie and Otsuka. AbbVie is a major biopharmaceutical company with significant neuroscience operations, while Otsuka is a Japanese pharmaceutical firm with a leading franchise in CNS and psychiatric medicine. These exits validate the fund's thesis that large pharma will pay a premium for de-risked CNS assets.
What stage of company does Negev Capital invest in?
Negev Capital invests at the early stage, spanning both seed and startup phases of company formation. The firm does not publicly detail whether these are drug-discovery targets or assets that have reached pre-clinical proof of concept. The strategy ultimately aims to hold positions until they become attractive to strategic acquirers.
Does Negev Capital co-invest or lead rounds?
Public information does not specify whether Negev Capital typically acts as a lead investor or participates in syndicates alongside other biotech venture firms. The concentrated and specialized nature of its CNS mandate would make the firm a logical syndicate partner for generalist biotech investors seeking domain expertise in a specific deal.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: